nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A personalised taper-to-target strategy with adalimumab in Crohn's disease
|
Dreesen, Erwin |
|
|
8 |
4 |
p. 293-294 |
artikel |
2 |
Breaking the unspoken rules of UK training in gastroenterology and hepatology
|
Raju, Suneil A |
|
|
8 |
4 |
p. 297-299 |
artikel |
3 |
Bringing organ preservation closer for selected patients with rectal cancer
|
Rutten, Harm J T |
|
|
8 |
4 |
p. 294-295 |
artikel |
4 |
Cause for concern: the rising incidence of early-onset pancreatic cancer
|
The Lancet Gastroenterology & Hepatology, |
|
|
8 |
4 |
p. 287 |
artikel |
5 |
Closing the gender gap in gastroenterology leadership
|
Bowker-Howell, Freya J |
|
|
8 |
4 |
p. 302 |
artikel |
6 |
Combination biologic therapy for ulcerative colitis
|
Vermeire, Severine |
|
|
8 |
4 |
p. 288-290 |
artikel |
7 |
Correction to Lancet Gastroenterol Hepatol 2023; 8: 343–55
|
|
|
|
8 |
4 |
p. e4 |
artikel |
8 |
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial
|
Borup, Christian |
|
|
8 |
4 |
p. 321-331 |
artikel |
9 |
Global reporting of progress towards elimination of hepatitis B and hepatitis C
|
Cui, Fuqiang |
|
|
8 |
4 |
p. 332-342 |
artikel |
10 |
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
|
Feagan, Brian G |
|
|
8 |
4 |
p. 307-320 |
artikel |
11 |
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
|
van Linschoten, Reinier C A |
|
|
8 |
4 |
p. 343-355 |
artikel |
12 |
Jo vs Cancer
|
Ashley-Norman, Phoebe |
|
|
8 |
4 |
p. 306 |
artikel |
13 |
Lessons from a trial of colesevelam for bile acid diarrhoea
|
Walters, Julian R F |
|
|
8 |
4 |
p. 290-291 |
artikel |
14 |
Management of inflammatory bowel diseases in older adults
|
Singh, Siddharth |
|
|
8 |
4 |
p. 368-382 |
artikel |
15 |
Mayflies: a drama limited by time
|
Moody, Joe |
|
|
8 |
4 |
p. 305 |
artikel |
16 |
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial
|
Gerard, Jean-Pierre |
|
|
8 |
4 |
p. 356-367 |
artikel |
17 |
Overcoming disparities for sexual and gender minority patients and providers in gastroenterology and hepatology: introduction to Rainbows in Gastro
|
Duong, Nikki |
|
|
8 |
4 |
p. 299-301 |
artikel |
18 |
Progress towards elimination of hepatitis C in the UK
|
Burki, Talha |
|
|
8 |
4 |
p. 303 |
artikel |
19 |
Research in Brief
|
Baker, Holly |
|
|
8 |
4 |
p. 304 |
artikel |
20 |
Strategic information to guide elimination of viral hepatitis
|
Hiebert, Lindsey |
|
|
8 |
4 |
p. 291-292 |
artikel |
21 |
Understanding and managing patients with overlapping disorders of gut–brain interaction
|
Balsiger, Lukas Michaja |
|
|
8 |
4 |
p. 383-390 |
artikel |
22 |
Universal hepatitis C virus screening and treatment as part of prenatal care
|
Marshall, Alison D |
|
|
8 |
4 |
p. 295-297 |
artikel |